Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer-Reference-Cited by-同舟云学术

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Published:2023-06 Issue:3 Volume:8 Page:101541
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Im S.-A.^ORCID,Gennari A.,Park Y.H.,Kim J.H.,Jiang Z.-F.,Gupta S.,Fadjari T.H.,Tamura K.,Mastura M.Y.,Abesamis-Tiambeng M.L.T.,Lim E.H.,Lin C.-H.,Sookprasert A.,Parinyanitikul N.,Tseng L.-M.,Lee S.-C.,Caguioa P.,Singh M.,Naito Y.,Hukom R.A.,Smruti B.K.,Wang S.-S.,Kim S.B.,Lee K.-H.,Ahn H.K.,Peters S.,Kim T.W.,Yoshino T.,Pentheroudakis G.,Curigliano G.,Harbeck N.

Funder

ESMO

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference134 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Male breast cancer: a population-based comparison with female breast cancer;Anderson;J Clin Oncol,2010

3. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study;Heer;Lancet Glob Health,2020

4. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019;Xu;Front Oncol,2021

5. A review of the epidemiology of breast cancer in Asia: focus on risk factors;Youn;Asian Pac J Cancer Prev,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The choice of optimal therapy for ER+ HER2-metastatic breast cancer (PROMETHEUS): all-Russian analysis of physicians’ preferences – updated survey results;Medical alphabet;2024-09-05

2. Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials;Oncology and Therapy;2024-08-02

3. Drug exposure and risk factors of maculopathy in tamoxifen users;Scientific Reports;2024-07-22

4. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer;Cancer Science;2024-07-09

5. Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study;Breast Cancer;2024-06-17